home / stock / xoma / xoma articles

XOMA Articles, XOMA Corporation

Stock Information
Company Name: XOMA Corporation
Stock Symbol: XOMA
Market: NASDAQ
Website: xoma.com
Menu
XOMA XOMA Quote XOMA Short XOMA News XOMA Articles XOMA Message Board
Get XOMA Alerts

News, Short Squeeze, Breakout and More Instantly...
XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ | Benzinga

EMERYVILLE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ:XOMA), the biotech royalty aggregator, announced today that member...
Lexicon Pharmaceuticals Reports Q1 Loss, Misses Revenue Estimates | Benzinga

Lexicon Pharmaceuticals (NASDAQ: LXRX) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.18. Th...

XOMA Corporation Announces Closing of Tender Offer | Benzinga

EMERYVILLE, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ:XOMA) ("XOMA" or the "Company"), a biotechnology royalty aggrega...

XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc. | Benzinga

EMERYVILLE, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- As previously announced on February 16, 2024, XOMA Corporation (("XOMA" or the "Company",...
XOMA to Present at Upcoming Investor Conferences in March | Benzinga

EMERYVILLE, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ:XOMA), the biotech royalty aggregator, announced today members of...

Biotech Royalty Aggregator XOMA To Acquire Small Cancer-Drug Developer Kinnate Biopharma | Benzinga

Friday, XOMA Corporation (NASDAQ:XOMA) agreed to acquire Kinnate Biopharma Inc (NASDAQ:KNTE) for a base cash price of $2.3352 p...

XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right | Benzinga

EMERYVILLE, Calif., Feb. 16, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ:XOMA) announced today it has entered an agreement to acquire Kinn...
XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA® Acquisition | Benzinga

XOMA provided an $8 million non-dilutive royalty capital solution to Talphera XOMA will receive a 15% royalty on all commercial sales and a signif...

FDA Acceptance of Zevra's Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to LadRx | Benzinga

EMERYVILLE, Calif., Jan. 11, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ:XOMA), the biotech royalty aggregator, announced today that based...

XOMA Names Owen Hughes as Chief Executive Officer and Appoints Jack L. Wyszomierski as Chairman of the Board of Directors | Benzinga

EMERYVILLE, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ:XOMA), the biotech royalty aggregator, announced today the Board ...
Next 10